Description
Cytokeratin 5 is a type II epithelial intermediate filament protein.{15723} It is composed of a central rod containing four α-helical domains, which are important for self-assembly, and non-helical head and tail domains at the N- and C-termini, respectively. Cytokeratin 5 is expressed in basal keratinocytes in the epidermis and is an integral component of the epithelial cell cytoskeleton.{58059} It dimerizes with the type I epithelial intermediate filament protein cytokeratin 14 via heptad repeats in the central rod domain to form a network of filament bundles throughout the cytoplasm.{58060,15723} Cytokeratin 5 interacts with β-catenin in estrogen receptor-positive breast cancer cells and promotes the reduction of β-catenin levels at the cell surface in vitro and in a patient-derived xenograft (PDX) mouse model of breast cancer.{58061} The expression of cytokeratin 5 in cancer cells predicts poor prognosis in estrogen receptor-positive breast cancer.{58061} Mutations in the tail or head domains of cytokeratin 5 induce cytoskeletal abnormalities and keratin aggregation and are associated with epidermolysis bullosa simplex (EBS) while head domain mutations are associated with Dowling-Degos disease.{58059,15723,58060} Cayman’s Cytokeratin 5 (C-Term; human) Rabbit Monoclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications.
Synonyms: CK5|CK-5|Cytokeratin-5|Keratin|Keratin-5|KRT5|Type II Cytoskeletal 5
Immunogen: Peptide from the C-terminal region of human cytokeratin 5
Formulation: 100 µl or 1 ml of protein A-affinity purified monoclonal antibody.
Isotype: IgG
Applications: IHC, WB
Origin:
Stability: 365 days
Application|Immunohistochemistry||Application|Western Blot||Product Type|Antibodies|Monoclonal Antibodies||Research Area|Cancer|Cell Signaling|Wnt Signaling||Research Area|Cell Biology|Cytoskeleton & Motor Proteins
